Discrepancy in SARS-CoV-2 Infection Status Among PCR, Serological, and Cellular Immunity Assays of Nucleocapsids: A Historical Cohort Study.

: Limited research has compared tests assessing humoral and cellular immunity related to SARS-CoV-2 infection. This study evaluated immunoglobulin G for nucleocapsid (IgG(N)) and T-spot for nucleocapsid (T-spot(N)) assays against polymerase chain reaction (PCR) test results for identifying infected individuals. : This study included participants who had completed five blood samplings since their second COVID-19 vaccination between 9 September 2021 and 6 November 2022. Chemiluminescent immunoassay (CLIA) tests measured the humoral immune response, IgG(S) and neutralizing activity tests the immune status, and IgG(N) tests the infection history. For cellar immunity, T-spot(S) indicated immune status, and T-spot(N) indicated infection history. : The primary outcome was the proportion of individuals who tested positive for PCR and the proportion who tested positive for IgG(N) and T-spot(N). Overall, this study included 2104 participants. In the PCR-negative group, 1838 individuals tested negative for IgG(N), whereas 64 tested positive at least once. The geometric mean of IgG(S) at T5 was 1541.7 AU/mL in the IgG(N)-negative group and 3965.8 AU/mL in the IgG(N)-positive group, which was 2.6 times higher. In the PCR-positive group, 25 individuals tested negative for IgG(N), while 177 tested positive at least once. The geometric mean of IgG(S) at T5 was 2700.6 AU/mL in the IgG(N)-negative group and 5400.8 AU/mL in the IgG(N)-positive group, showing higher values in the IgG(N)-positive group. : A discrepancy was noted between PCR test results and the IgG(N) and T-spot(N) determinations. Combining multiple assays is required to accurately identify the past-infected population.